Raymed Labs Ltd Stock Price Today (NSE: RAYLA)
Fundamental Score
Raymed Labs Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Raymed Labs Ltd share price today is ₹3.83, up +0.00% on NSE/BSE as of 2 January 2026. Raymed Labs Ltd (RAYLA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.64 (Cr). The 52-week high for RAYLA share price is ₹N/A and the 52-week low is ₹N/A.
Raymed Labs Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Raymed Labs Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Raymed Labs Share Price Analysis: ROCE Efficiency Concerns
The pharmaceutical industry, known for its long development cycles and stringent regulatory hurdles, relies heavily on efficient capital allocation to generate returns. This analysis examines the current state of Raymed Labs Ltd, focusing specifically on its Return on Capital Employed (ROCE) efficiency. Currently, the Raymed Labs share price stands at ₹3.83, and the company’s reported Price-to-Earnings (PE) ratio and ROCE are both unavailable (None%). The lack of data regarding these fundamental metrics raises immediate concerns about the company's profitability and capital management.
The absence of a ROCE figure is particularly alarming. ROCE measures how effectively a company is using its capital to generate profits. A "None%" ROCE suggests either significant losses or a complete inability to generate returns from invested capital. This severely impacts the company's potential to build a sustainable competitive advantage, or "moat." Without profitable reinvestment, it will be difficult for Raymed Labs to fund future growth or maintain its position within the competitive pharmaceutical landscape.
Comparing Raymed Labs Ltd to its peers, such as
Mankind Pharma Ltd, further highlights the severity of the situation. While specific ROCE figures for peers aren’t available here, established pharmaceutical companies typically demonstrate a strong correlation between competent management and capital deployment efficiencies that translate into healthy ROCE figures. One could reasonably hypothesize that established players like Mankind Pharma Ltd possess stronger managerial expertise, leading to more effective resource allocation. Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd, other sector peers, likely operate with a demonstrable ROCE, signifying a degree of capital efficiency not currently evident in Raymed Labs' data.The unavailable PE ratio further compounds the concerns. A missing PE ratio often implies the company is not profitable, as earnings are a denominator in its calculation. Given the current data void, significant due diligence is required before considering investment in Raymed Labs Ltd. This analysis, part of an 80-parameter fundamental audit verified by Sweta Mishra, is purely observational and focuses on publicly available data. It does not constitute financial advice and should not be interpreted as a buy or sell recommendation for Raymed Labs share price.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Raymed Labs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of RAYLA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (50.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
4 factors identified
Weak Interest Coverage (-1.55x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-2.25 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.96%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Raymed Labs Ltd Financial Statements
Comprehensive financial data for Raymed Labs Ltd including income statement, balance sheet and cash flow
About RAYLA (Raymed Labs Ltd)
Raymed Labs Ltd (RAYLA) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.64 (Cr). Investors tracking RAYLA share price can monitor key metrics including P/E ratio, promoter holding of 32.27%, and quarterly earnings growth.
Company Details
RAYLA Share Price: Frequently Asked Questions
What is the current share price of Raymed Labs Ltd (RAYLA)?
As of 02 Jan 2026, 04:03 pm IST, Raymed Labs Ltd share price is ₹3.83. The RAYLA stock has a market capitalisation of ₹1.64 (Cr) on NSE/BSE.
Is RAYLA share price Overvalued or Undervalued?
RAYLA share price is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the Raymed Labs Ltd stock appears to be Fairly Valued against its sector peers.
What is the 52-week high and low of RAYLA share price?
The 52-week high of RAYLA share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Raymed Labs Ltd share price?
Key factors influencing RAYLA share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Raymed Labs Ltd a good stock for long-term investment?
Raymed Labs Ltd shows a 5-year Profit Growth of N/A% and an ROE of N/A%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of N/A before investing in RAYLA shares.
How does Raymed Labs Ltd compare with its industry peers?
Raymed Labs Ltd competes with major peers in the Pharmaceuticals. Investors should compare RAYLA share price P/E of 0.00x and ROE of N/A% against the industry averages to determine competitive standing.
What is the P/E ratio of RAYLA and what does it mean?
RAYLA share price has a P/E ratio of N/Ax compared to the industry average of 31.77x. Investors pay ₹N/A for every ₹1 of annual earnings.
How is RAYLA performing according to Bull Run's analysis?
RAYLA has a Bull Run fundamental score of 8/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does RAYLA belong to?
RAYLA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Raymed Labs Ltd share price.
What is Return on Equity (ROE) and why is it important for RAYLA?
RAYLA has an ROE of N/A%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Raymed Labs Ltd generates profits from shareholders capital.
How is RAYLA debt-to-equity ratio and what does it indicate?
RAYLA has a debt-to-equity ratio of N/A, which indicates conservative financing with low financial risk.
What is RAYLA dividend yield and is it a good dividend stock?
RAYLA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Raymed Labs Ltd shares.
How has RAYLA share price grown over the past 5 years?
RAYLA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in RAYLA and why does it matter?
Promoters hold 32.27% of RAYLA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Raymed Labs Ltd.
What is RAYLA market capitalisation category?
RAYLA has a market capitalisation of ₹2 crores, placing it in the Small-cap category.
How volatile is RAYLA stock?
RAYLA has a beta of N/A. A beta > 1 suggests the Raymed Labs Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is RAYLA operating profit margin trend?
RAYLA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is RAYLA quarterly performance?
Recent quarterly performance shows Raymed Labs Ltd YoY Sales Growth of N/A% and YoY Profit Growth of 50.00%.
What is the institutional holding pattern in RAYLA?
RAYLA has FII holding of 0.00% and DII holding of 0.96%. Significant institutional holding often suggests professional confidence in the Raymed Labs Ltd stock.